Sub-Therapeutic Doses in the Treatment of Depression: The Implications of Starting Low and Going Slow by de Jong, Veronica & Raz, Amir
m
br
.s
yn
er
gi
es
pr
ai
ri
es
.c
a
73 || MBR || Volume : 1 || Issue : 2
art ic le
Sub-Therapeutic Doses in the Treatment of Depression:
The Implications of Starting Low and Going Slow
Veronica J. de Jong, BA&Sc *; Amir Raz, PhD *, † 
* McGill University/
Lady Davis Institute, 
Department of Psy-
chiatry
† To whom corre-
spondence should be 
addressed:
Duff Medical Building 
#103 at the Montreal 
Neurological Institute 
3775 University Street 
Montreal, Quebec 
H3A 2B4
email: amir.raz@
mcgill.ca
Psychiatrists who opt to treat depression with antidepressant medication typically “start low and 
go slow” — initially prescribing modest doses and then gradually increasing them.  General prac-
titioners, moreover, tend to prescribe low, even sub-therapeutic, maintenance doses of antidepres-
sants.  Indeed, some patients report clinical improvements even while taking extremely low-dose 
medication.  Several meta-analytic findings suggest a negligible clinical benefit of antidepressants 
over placebos for the treatment of mild-to-moderate depression; of note, both interventions im-
prove depression ratings compared to no-treatment.  Do sub-therapeutic doses of antidepressants 
provide a treatment prospect for healthcare professionals who wish to use placebo-like treatments 
for depression?  An independent line of research supports the notion of a clinically meaningful dif-
ference between antidepressants and placebo but suggests that antidepressants can often achieve 
this difference at doses much lower than those currently recommended.  Could the use of sub-
therapeutic doses signal attempts at capturing efficacy at below conventional doses?  In this paper, 
we use results from psychiatrist interviews to explore the vagaries of sub-therapeutic doses and 
shed light on their role in the armamentarium of the modern clinician. 
Introduction
Depression, as currently defined, is ubiquitous; 
however, treatment of this potentially debilitat-
ing condition raises many challenges.  More than 
12% of the Canadian population will suffer from 
depression at some point in their lives (Patten 
et al., 2006), with even higher prevalence rates 
(> 16%) in the United Kingdom (Bird, 1999) and 
the United States (Kessler et al., 2005).  In the 
last decade, the efficacy of antidepressant medi-
cation — a backbone drug of modern psychia-
try (Ioannidis, 2008) — has come under intense 
scrutiny (Pigott, Leventhal, Alter, & Boren, 2010). 
Findings from independent meta-analyses sug-
gest that antidepressants and placebos hardly 
differ in clinical benefit, especially for the treat-
ment of mild-to-moderate depression (Fournier 
et al., 2010; Khan, Leventhal, Khan, & Brown, 
2002; Khan, Redding, & Brown, 2008; Kirsch et 
al., 2008; Kirsch, Moore, Scoboria, & Nicholls, 
2002; Kirsch & Sapirstein, 1998; Rief et al., 2009). 
The rationale behind the “anti” prefix in antide-
pressant is grounded in the chemical imbalance 
theory (Moncrieff, 2007) — a controversial view 
purporting that depression is a consequence of 
neurotransmitter shortage.  The scarcity of scien-
tific evidence supporting the chemical imbalance 
theory as a comprehensive theory for depression 
(Ioannidis, 2008; Kirsch, 2009; Ruhé, Mason, 
& Schene, 2007) raises uncertainty as to the 
biological nature of depression (Beck & Alford, 
2009; Lacasse & Leo, 2005).  Nonetheless, clini-
cians appear comfortable prescribing antidepres-
sants to their depressed patients.
Another controversial account proposes that 
antidepressants are clinically effective at sub-stan-
dard doses (Cohen, 2001b; Furukawa, McGuire, & 
Barbui, 2002; McCormack, Allan, & Virani, 2011; 
Zilberman, Gorenstein, & Gentil, 2010).  Standard 
starting dose represents the lowest tested amount 
that elicits a statistically significant benefit over 
placebo (Sheiner, Beal, & Sambol, 1989), and any-
thing below this benchmark is conventionally 
considered sub-therapeutic.  The small quantity 
of active biochemical material in such doses is 
likely to cause no clinical outcome — homeopathic 
dilutions being an extreme case.  Recent reconsid-
eration of early fluoxetine (Prozac) studies (Cain, 
1992; Louie, Lewis, & Lannon, 1993; Wernicke, 
1988) supports the idea of “starting low” — as low 
as one quarter (McCormack, et al., 2011) or even 
one eighth (Cohen, 2001b) of the recommended 
initial dose found in the product monograph.
Considering the evidence that placebos repli-
cate the bulk of antidepressant drug effects, frac-
tional dose treatments are likely also exerting their 
effects through placebo mechanisms.  Teasing 
apart the pharmacological influence of sub-ther-
apeutic dose from non-drug effects reifies the pre-
carious relationship between low-dose and pla-
cebo.  At a certain dose range, drug concentration 
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is too low to exert an effect better than placebo. 
If no such limit exists with antidepressants, we 
can further contextualize their lack of chemical 
specificity on depressed mood — a fundamen-
tal element of the “antidepressants vs. placebos” 
conundrum. 
In light of the contentious state of research on 
antidepressant medication, we sought to investi-
gate how academic clinicians with experience in 
direct patient care treat depression in the clinic. 
In this integrative synthesis, we position sub-
therapeutic doses and non-drug effects as vehicles 
to probing underlying clinical conceptualizations 
of the pharmacological treatment of depression. 
Relying on insights gleaned from interviews with 
psychiatrists associated with Canadian universi-
ties, we sketch conceptual challenges and uncover 
tacit attitudes in the contemporary treatment of 
depression.  Prior to this, we present a review of 
the current literature on placebo and low-dose 
treatments for depression.   
Background and the current 
state of affairs
Placebo Effects in the Treatment 
of Depression
Mounting psychological, brain imaging, and 
clinical trial evidence sheds light on the role of 
placebos in treating depression (Ankarberg & 
Falkenström, 2008; Kirsch, 2009; Mayberg et al., 
2002).  One of the most contentious research re-
sults has emerged from a trailblazing trajectory 
of meta-analytic studies examining placebo-con-
trolled clinical trials of antidepressants (Fournier, 
et al., 2010; Khan, et al., 2002; Khan, et al., 2008; 
Kirsch, et al., 2008; Kirsch, et al., 2002; Kirsch & 
Sapirstein, 1998; Rief, et al., 2009).  Such studies 
independently reported modest benefits of anti-
depressants over placebos, especially for the treat-
ment of mild-to-moderate depression.  
In one of the first meta-analyses (Kirsch & 
Sapirstein, 1998), the investigators included a no-
treatment control group in order to determine the 
extent to which the response in the placebo group 
resulted from meaningful placebo effects*,†.  Their 
data demonstrated that taking placebo or an anti-
depressant improved depression symptom ratings 
to nearly the same extent; receiving no treatment 
did very little for depression outcomes.  
In order to circumvent publication bias 
towards positive trials (Turner, Matthews, 
Linardatos, Tell, & Rosenthal, 2008), Kirsch 
and his colleagues used the US Freedom of 
Information Act to pool results from both the 
published and unpublished trials submitted to the 
US Food and Drug Administration (FDA) (2002). 
With the unpublished data included, their meta-
analysis of the top prescribed antidepressants 
revealed results with even greater magnitude: 
placebo pills duplicated 80% of the antidepres-
sant effect.  The resultant mean difference on 
the Hamilton Depression Scale was too minute 
to constitute clinical significance according to 
the National Institute for Clinical Excellence 
(NICE) guidelines (National Institute for Clinical 
Excellence, 2004)‡.  
Depression is a heterogeneous condition, 
characterized in part by a spectrum of severity 
(Chen, Eaton, Gallo, & Nestadt, 2000; Weissman 
et al., 1986).  Kirsch and colleagues’ 2002 meta-
analysis did not consider the potential relation-
ship between initial depression severity and drug 
versus placebo benefits (Elkin et al., 1989; Wilcox 
et al., 1992).  Subsequent independent meta-
analyses (Fournier, et al., 2010; Khan, et al., 2002; 
Kirsch, et al., 2008) sought out this relationship 
and found such a link.  Importantly, however, the 
increasing benefit of antidepressants over place-
bos only reached clinical significance in severely 
depressed individuals (Fournier, et al., 2010; 
Kirsch, et al., 2008).  Many have suggested that 
the marginal difference between antidepressant 
and placebo effectiveness may be at least partly 
accounted for by patients breaking blind — a fre-
quent occurrence due to the absence of common 
antidepressant side effects from inert placebo 
pills (Gaudiano & Herbert, 2004; Kirsch, 2009; 
Kirsch & Rosadino, 1993; Moncrieff, Wessely, & 
Hardy, 2004; White, Kando, Park, Waternaux, & 
Brown, 1992).  From the clinical trial research, 
placebos appear as effective as antidepressants in 
the treatment of mild-to-moderate depression, 
but how this information translates to the clinical 
setting remains uncertain.
Low-Dose Medication in the Treat-
ment of Depression 
A revealing meta-analytic finding from the 
pooled placebo-controlled antidepressant tri-
als demonstrated that dosage was unrelated to 
the level of improvement (Kirsch, et al., 2002). 
In fact, for the majority of the commonly pre-
scribed selective serotonin reuptake inhibitors 
(SSRIs) (Hemels, Koren, & Einarson, 2002), no 
dose-response relationship has been clearly es-
tablished (Bijl et al., 2008; Wood & Gram, 1994). 
Further, for antidepressants such as fluoxetine, a 
lower limit of effective dose evades documenta-
tion.  These findings, or lack thereof, do not lend 
support to a pharmacological explanation for an-
tidepressant action. 
Findings from a recent analysis suggest 
equivalent fluoxetine efficacy among 40mg, 
20mg — the current convention for minimum 
† Placebo effects  
are psychobiological changes 
generated through the clini-
cal encounter that are not 
attributable to the inherent 
chemical or physical proper-
ties of the intervention. 
Factors that contribute to 
placebo effects include the 
expectations and beliefs of 
the patient; the conditioned 
response to a treatment; 
the patient-practitioner 
relationship; the attention, 
attitude and personal char-
acteristics of the caregiver; 
and the context in which the 
treatment is given.
 
‡ Clinical Significance 
Clinical trials can be selec-
tively designed to produce 
statistically significant 
results according to formal 
conventions (p < 0.05) that 
are trivial in the clinic. For 
trials assessing depression 
ratings, a consensus by 
the National Institute for 
Clinical Excellence has sug-
gested that at least a 3-point 
difference is required in 
the Hamilton Depression 
51-point Scale to state a 
clinically important effect.  
* Placebo responses 
are the outcomes generated 
in the placebo group of a 
clinical trial.  Improvements 
in this group can be at-
tributed not only to placebo 
effects but to a host of non-
specific factors including 
spontaneous remission (e.g., 
recovery from the common 
flu), regression towards 
the mean (the tendency 
for measurements to revert 
to average levels), natural 
history of the disease (e.g., 
the episodic nature of mood 
disorders), and external 
changes in the patient’s life.
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effective dose — and 5mg (McCormack, et al., 
2011 cf Wood & Gram, 1994).  Based on efficacy 
evidence and with the intent of minimizing costs 
and harms, the authors recommend starting med-
ications at half or even one-quarter the standard 
starting dose in several conditions, including de-
pression.  They further assert that a very low dose 
provides a compromise between capturing the 
placebo effect and providing a legitimate therapy.
Several reviews support the low-dose ap-
proach to treatment, claiming that existing guide-
lines are over-inflated.  Cohen reported (2001b, 
2004) that, when establishing the dosing recom-
mendations, members of industry and regula-
tory agencies suppressed or ignored the early 
low-dose fluoxetine studies (Cain, 1992; Louie, et 
al., 1993; Wernicke, 1988) and reviews (Salzman, 
1990; Schatzberg, 1991; Schatzberg, Dessain, 
O'Neil, Katz, & Cole, 1987; Stewart, Quitkin, & 
Klein, 1992; Wood & Gram, 1994).  A number of 
other antidepressants seem to have inflated dos-
ing guidelines — for example, drugs such as bu-
proprion, citalopram, escitalopram, fluvoxamine, 
mirtazapine, nefazodone, paroxetine, sertraline, 
and venlafaxine — prompting recommendations 
to start them at doses as low as one eighth of the 
guidelines appearing in the product monographs 
(Cohen, 2001a, 2001b, 2004).  Striving for the 
lowest possible therapeutic dose is certainly an 
admirable clinical virtue; however, we must jux-
tapose the evidence for low-dose efficacy with the 
evidence for the placebo component of antide-
pressant action.  The question remains: How do 
clinicians mobilize this information when ratio-
nalizing antidepressant prescriptions and dosing?
Sub-therapeutic doses in the clinic 
In a recent effort to assess the controversial top-
ic of placebos in medical practice, Raz and col-
leagues surveyed over 600 Canadian physicians 
about their use of certain treatments in situations 
without demonstrated or expected benefits (2011). 
Results revealed that 38% of psychiatrists admin-
ister sub-therapeutic doses of medication — a fre-
quency of over six-times that of non-psychiatrists. 
Interestingly, only 6% of the surveyed psychia-
trists both administer sub-therapeutic doses and 
admit to having used a placebo in routine clinical 
practice (Raz, et al., 2011).  Moreover, only 2% of 
the 257 psychiatrist respondents deemed placebos 
of no clinical benefit.  These intriguing findings 
raise several questions that are especially relevant 
to the antidepressant context. 
In primary care, a number of sources suggest 
that physicians also administer sub-therapeutic 
doses and more specifically, for the treatment of 
depression (Beaumont, Baldwin, & Lader, 1996; 
Gilbody, Sheldon, & Wessely, 2006; Katon, Von 
Korff, Lin, Bush, & Ormel, 1992).  Unlike psychi-
atrists, however, the evidence of sub-therapeutic 
dosing in primary care comes from third party 
assessments of depression treatment in that set-
ting.  Critical accounts suggest that primary care 
physicians are treating depression sub-optimally 
by prescribing sub-therapeutic doses either un-
knowingly or out of over-cautiousness.  This is 
supported, at least in part, by the survey finding 
that psychiatrists admit to using sub-therapeutic 
doses significantly more than other types of phy-
sicians (Raz, et al., 2011).  
Establishing a clear consensus for what con-
stitutes a sub-therapeutic dose may elucidate why 
psychiatrists prescribe them.  Perhaps they are 
using these treatments as “convenient placebos.” 
A very low dose of medication could occupy the 
middle ground between a pure placebo and a 
full dose of biochemically active drug.  The use 
of such doses would not require deception; the 
side effect warnings, the chemical formula, the 
appearance and the name are all true representa-
tions that contribute to the aura and suggestion 
of taking a drug.  
Could prescribing sub-therapeutic doses be a 
way of acknowledging the aforementioned find-
ings on antidepressants and placebos without 
venturing into the dubious domain of handing 
out pure placebos?  Alternatively, could the use of 
such doses signal attempts at capturing insights 
from the low-dose literature with the aims of 
achieving therapeutic efficacy at below conven-
tional doses?  The present investigation aims to 
shed light on these questions while unearthing 
clinical realities of the treatment of depression. 
Methods
We interviewed academic psychiatrists concern-
ing their current conceptualizations of low-dose 
antidepressants for the treatment of depression. 
Specifically, we sought motivations for prescrib-
ing sub-therapeutic doses of medication.
Participants
The interviews were conducted on practicing, 
university affiliated attending psychiatrists in the 
Toronto and Montreal areas.  We targeted these 
professionals because of their accessibility and 
expertise.  We enlisted the assistance of a senior 
psychiatrist to recommend experts who would be 
able to provide a meaningful commentary on the 
subject matter.  Out of 37 psychiatrists whom we 
contacted, we interviewed all 15 who responded 
favourably to our request.  All participants had 
experience treating depression.  VdJ conducted 
all interviews.
76 || MBR || Volume : 1 || Issue : 2
ar t ic le The Journal of Mind–Body Regulation
m
br
.s
yn
er
gi
es
pr
ai
ri
es
.c
a
The Interviews
Each interview consisted of a semi-structured 
half-hour interview comprising 13 open-ended 
questions (see Appendix for the list of questions). 
The interviewer memorialized the conversations, 
which were then transcribed for analysis.
Analysis
We performed a qualitative analysis on the in-
terview results using a modified version of the 
thematic content analysis method proposed by 
Burnard (1991).  The methodology involved re-
visiting interview transcripts and notes and iden-
tifying salient themes.  Next, we reviewed the 
transcripts to categorize interview responses ac-
cording to each theme.  After thorough analysis 
of the results with respect to the aims of this study 
(Strauss, 1987) we rejected the themes that were 
no longer relevant and collapsed the remaining 
themes into the following categories:
1) Working definitions of a sub-therapeu-
tic dose of medication.
2) Rationales for prescribing sub-thera-
peutic doses. 
3) Opinions on the placebo effect compo-
nent of depression treatment.
4) Alterations, communication tactics, 
and patient conceptualizations of dose 
levels.
We identified and counted patterns of similar 
responses within each category.  In addition, we 
highlighted particularly intriguing responses and 
quotations. 
Results and discussion
1) Working definitions of a sub-
therapeutic dose of medication. 
Results. With the exception of one confidant psy-
chiatrist, participants did not seem to have a for-
mal medical definition of sub-therapeutic dose 
readily available to draw upon. When pressed fur-
ther, participants came up with one of three broad 
working definitions for the term.  The most com-
mon definition (number of participants (N) = 9) 
was a dose below the established level of efficacy 
from the published literature (e.g., drug mono-
graph reference books, evidence based practice 
guidelines, systematic reviews or meta-analyses). 
Another common definition (N  =  6), given in 
addition to the above definition by three partici-
pants, was any dose where no therapeutic benefit 
can be observed in the individual patient.  Lastly, 
three participants construed sub-therapeutic as a 
dose below the therapeutic level of a drug’s primary 
use but with beneficial effects from its off-label or 
secondary indications.  
All but two participants indicated caveats to 
the definitions or provided additional comments 
in light of the antidepressant context.  A major 
issue was that of inter-individual variability in 
response to antidepressants — attributed largely 
to differences in metabolism.  Unpredictable 
outcomes propelled participants to offer a defini-
tion of what constitutes a sub-therapeutic dose 
based on either literature averages with the ca-
veat, “which may have beneficial effects for some 
patients” or based on response in individual pa-
tients, adhering to the literal nature of the term. 
Seven participants highlighted the difficulties in 
predicting patient sensitivity to a new prescrip-
tion.  However, two participants mentioned that 
they can approximate the sensitivity of a patient 
to a new drug based on drug history since pat-
terns of similar responses often exist between 
drug classes.  Regardless of being able to pre-
dict sensitivity, almost all participants (N  =  13) 
reported that they occasionally see unexpected 
improvement to doses of antidepressants that are 
below established levels of therapeutic efficacy.  
When questions concerning the limits of a 
sub-therapeutic dose arose, it became apparent 
that its lower limit is, as yet, undefined.  In par-
ticular, participants were unable to provide clear 
responses to how one could distinguish between 
a sub-therapeutic dose, a homeopathic remedy, 
and a placebo.  Similarly, they were largely unable 
to define what, if any, is the range of sub-thera-
peutic ‘efficacy’.  However, three participants did 
provide reasons for our limited knowledge in that 
only a sub-set of doses are clinically tested and 
appear in the published literature, and an even 
smaller sub-set are commercially available.  
Discussion. For the purposes of this discussion 
and for the remainder of the interview, we use 
the term “sub-therapeutic” in reference to a dose 
below the minimal effective dose stated in each 
drug’s product monograph.  Formally defined, a 
sub-therapeutic dose means “below the dosage 
levels used to treat diseases” (Sub-therapeutic, 
2000) or “indicating a dosage less than the 
amount required for a therapeutic effect ” 
(Subtherapeutic, 2011).  The complex patient vari-
ability in responses to antidepressant medication, 
however, seems to complicate these definitions.
The drug literature determines threshold 
doses by averaging individual responses; a dose 
exerting no therapeutic effect for the majority of 
patients, however, may be therapeutically active 
for others.  Environmental, pathophysiological 
and genetic factors contribute to the inter-indi-
vidual variability in drug response.  Variation in 
the efficacy of drug metabolizing enzymes is a 
key differentiating factor (Meyer & Zanger, 1997). 
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Five to ten percent of the Caucasian population 
have genetic polymorphisms in the cytochrome 
P450 enzyme, CYP2D6, that render them poor 
metabolizers of several commonly prescribed 
antidepressants (Sachse, Brockmöller, Bauer, & 
Roots, 1997).  However, uncertainty lingers as to 
how and whether these phenomena wield clini-
cal effects (Bijl, et al., 2008).  When it comes to 
depression outcomes, the data have yet to sub-
stantiate a clear influence of the most frequent 
CYP2D6 polymorphisms on clinical responses 
to antidepressants, especially SSRIs.  As such, ge-
netic screening to optimize treatment outcomes 
remains elusive (Bijl et al., 2008) and serum drug 
level testing is rare.  Although a few participants 
mentioned drug response history as a helpful 
guide to antidepressant sensitivity, systematically, 
the clinician does not know how much of the ac-
tive compound is reaching a patient’s brain.  It 
does not appear that patient variability is easily 
accounted for by metabolism alone and the clini-
cian has little way of delineating the cause of an 
unexpected drug response.  Further, even the use 
of sophisticated genetic tools does not seem to 
provide any clearer answers. 
Only three participants gave voice to limita-
tions in understanding lower limits of effective 
dose based in practical issues that resonate with 
those of the low-dose literature (Cohen, 2001a, 
2001b, 2004; McCormack, et al., 2011).  Although 
inflated dosing guidelines may obscure a clear 
conceptualization between a sub-therapeutic 
and a conventional dose of antidepressant, most 
participants highlighted individual variability in-
stead.  Moreover, the general inability of partici-
pants to define a limit between a sub-therapeutic 
dose and a placebo may suggest a broader con-
ceptual grey zone extending from conventional 
dose entirely to placebo.
2) Rationales for prescribing sub-
therapeutic doses. 
Results. The majority of participant psychiatrists 
stated that administering sub-therapeutic doses 
of medication did not equate to giving a pla-
cebo.  This sentiment was well-summarized by 
one participant who said, “If [a sub-therapeutic 
dose] were the same as a placebo, then you could 
give just about anything.”  By partial exception, 
one participant asserted: the only utility for a sub-
therapeutic dose of drug intended for its primary 
indication would be for the placebo effect.  He 
added that he would never prescribe medication 
with this rationale. 
Since it did not seem that participants could 
be prescribing sub-therapeutic doses for their 
placebo-like qualities, we questioned what other 
rationales they may have.  The situations in which 
participants recalled prescribing sub-therapeutic 
doses of antidepressants were mostly when initi-
ating the “start low, go slow” titration technique. 
Four of the participants that reported using this 
technique added that they usually start with the 
minimum therapeutic dose instead of a sub-ther-
apeutic one, especially in the adult population. 
Two-thirds of participants emphasized tolerance 
building and minimizing side effects as the ratio-
nale for slowly increasing the dose from a low lev-
el.  Three participants stated that starting at lower 
doses can also provide a level of comfort or al-
lay anxiety.  One participant reported this reason 
as a primary rationale for starting at such doses. 
Striving for the lowest effective dose, regardless 
if it were below conventional levels, was the ra-
tionale for starting low between two participants. 
With the exception of these two, the consensus 
among participants was that they do not expect 
any clinical benefit until the patient reaches the 
established therapeutic dose range.
Since most participants reported that they 
had seen unexpected responses to sub-therapeu-
tic doses, we sought potential explanations.  Nine 
of the participants arrogated sub-therapeutic 
dose responses in physiological terms: the patient 
must “lie on the lower end of the response curve,” 
or be “sensitive to the medication,” or “a poor 
metabolizer.”  Six participants acknowledged that 
the response could be due to placebo effects but 
with no easy way of uncoupling them from the 
other factors at play.  Two participants belittled 
the need to pinpoint the cause of a satisfactory 
therapeutic response, especially through costly 
genetic testing.  One participant, however, articu-
lated that readily available genetic testing would 
be beneficial in certain cases.  
Participants also brought up the issue of the 
exact psychophysical target of antidepressants. 
Substantial therapeutic benefits can occur from 
a dose of antidepressant that is sub-therapeutic 
for managing depressed mood and negative cog-
nitive symptoms, but may relieve certain symp-
toms, sometimes to the extent that the patient’s 
condition is much improved.  Three participants 
acknowledged that the sedative side effects of cer-
tain antidepressants can help depressed patients 
struggling with insomnia get some much-needed 
rest.  One of them explained that sometimes all 
a patient needs is a few good nights of sleep to 
make a significant difference in his or her life.  A 
similar conception was the ability of antidepres-
sants to “take some of the edge off ” or produce a 
“halo effect” in relieving sub-clinical anxiety of-
ten comorbid with depression.  
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Discussion. Most people construe placebos as in-
ert.  A more nuanced approach, however, includes 
treatments that are inert for the specific condition 
but that may otherwise contain active substances 
(Raz, et al., 2011).  Examples of this type of pla-
cebo include antibiotics for viral infections, vita-
mins for the common cold, herbal preparations 
lacking demonstrated efficacy, and, arguably, sub-
therapeutic medications.  The opinion among 
participants that placebos are not equivalent to 
sub-therapeutic doses parallels recent findings 
suggesting that the majority of psychiatrists who 
have administered sub-therapeutic doses in situa-
tions of no expected or demonstrated clinical effi-
cacy claim to have never used a placebo in clinical 
care (84%) (Raz, et al., 2011).
Participants revealed various treatment nu-
ances through their comments on prescribing 
sub-therapeutic doses.  It would seem that partic-
ipants distinguished sub-therapeutic doses from 
placebo in terms of intention: although placebo 
effects may be responsible for the improvement 
of some patients on a minimal dose, this was not 
the intended mechanism of action. The intention 
of most participants starting antidepressant pre-
scriptions low, moreover, was not to capitalize on 
findings of low-dose efficacy
Rationales for prescribing sub-therapeutic 
doses seem grounded more in reducing side ef-
fects than in enhancing non-drug effects, neither 
of which follow the classic drug-target convention 
akin to biomedical pharmacology.  Select psychi-
atrists did demonstrate a certain level of tact in 
their off-label and psychologically grounded uses 
of low-dose antidepressants — many of which re-
quire tacit clinical knowledge beyond that which 
can be gleaned from the available evidence base. 
However, the existing evidence on low-dose ef-
ficacy and the substantial placebo component of 
antidepressant treatment does not appear to have 
exerted an influence on prescribing practices 
among the participant psychiatrists. 
3) Opinions on the placebo effect 
component of depression treat-
ment.
Results. Placebo effects in the treatment of de-
pression were common knowledge among par-
ticipant psychiatrists.  They did not comfortably 
attribute sub-therapeutic dose improvement 
solely to placebo effects, however, as they often 
conceived placebo effects as transitory and out-
lasted by pharmacological effects.  Even with 
improvement on a sub-therapeutic dose, three 
participants mentioned that they would increase 
the dose to the minimum established therapeutic 
level.  Nonetheless, all participants highlighted 
the importance of additional factors involved in 
the clinical encounter that are not specific to the 
treatment modality. 
Participants consistently stressed the impor-
tance of patient choice and willingness to use 
pharmacological treatments.  All participants 
said they strongly attend to patient attitudes to-
wards using medications.  Participants reported 
that many patients are wary of taking medication 
for psychiatric disease.  Such reluctance, some 
suggested, may reflect patient concerns rooted in 
stigmatization and acceptance of mental illness; 
other patients fear side effects or ineffectiveness 
of the medication.  On the one hand, two partici-
pants emphasized that the treatment effects are 
likely to diminish if a patient does not believe in 
the treatment modality.  One of these participants 
often explains this sentiment to patients:  “If you 
think it is going to work, it is probably going to 
have a different effect than if you take it reluc-
tantly.  It is important to talk about whether you 
think I am shoving this down your throat, or if 
you actually believe in it.”  He elaborated: “Even 
the strongest doses of medications will have little 
chance of producing satisfactory outcomes if the 
patient is not convinced that they will work.”  The 
other participant reported taking pride in be-
ing able to convince patients that the treatment 
recommendation is a favourable option.  On the 
other hand, many participants cautioned against 
over-inflating the efficacy of drug treatments to 
their patients to ensure realistic goals.  
According to participants, a sub-group of 
patients seek out drug treatment or rely heavily 
on notions of using medications to “fix” chemi-
cal imbalances.  Pamphlets adorning the par-
ticipants’ waiting rooms clearly communicate 
this explanation to patients.  One such pamphlet 
(“made possible by an unconditional grant from 
Wyeth Canada”) writes: 
Depression is often described as a “chem-
ical imbalance” in the brain. What this 
means is that certain neurotransmitters 
(your brain chemicals) are not at the 
levels they should be to maintain a posi-
tive mood .  .  . The most common treat-
ment for depression involves medication 
designed to increase the levels of these 
neurotransmitters and thus, improve 
your mood (Mood Disorders Society of 
Canada, 2009).
Participants rarely broached the subject of 
antidepressant neurochemical mechanisms.  The 
only two such iterations were: an explanation 
of how SSRIs can produce an instant “serotonin 
kick” in the brain but not always treat the target, 
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and a mechanistic explanation that was cut-short 
due to the participant’s perception that the inter-
viewer (a researcher) may be more of an expert 
in this area. 
Two participants reported that anecdotally 
based notions of drug treatment can influence 
outcomes through belief effects.  Based on per-
sonal accounts from family and friends, patients 
can arrive at their first appointment with stubborn 
ideas of what will or will not work, sometimes 
with a specific drug already in mind.  According 
to these participants, prescribing in-line with pa-
tient requests can lead to a type of placebo effect. 
Discussion. The strongly held notion that placebo 
effects are only transitory — although findings re-
fute this assumption (Khan, et al., 2008)  — seems 
to create reluctance in attributing antidepressant 
responses to such effects alone.  Our findings sug-
gest that psychiatrists utilize placebo effects in 
more subtle ways in order to enhance the effec-
tiveness of drug treatment.  Engaging in patient 
belief systems to recruit conviction in the treat-
ment seems critical to maximizing therapeutic 
outcomes; at least one empirical study would 
support this notion in terms of improving ad-
herence to antidepressants (Aikens, Nease, Nau, 
Klinkman, & Schwenk, 2005).
Participants who emphasized the importance 
of mobilizing patients’ anecdotally based percep-
tions in medications demonstrated the integration 
of belief effects — independent of biochemical ef-
fects — into prescribing practices.  Neurochemical 
based beliefs in depression treatment, borne out 
of the popular chemical imbalance theory of de-
pression, are likely ingrained in many patients 
(Leo & Lacasse, 2008); however, from the inter-
views, it is not clear whether or not psychiatrists 
have rejected the theory.  It is possible that, de-
spite uncertainty in the field, psychiatrists per-
petuate this theory, at least indirectly, as a simple 
explanation for the proposed drug treatment
Whether communicated subtly or overtly, 
accurately or imprecisely, the meaning imbued 
in the ability of a drug to fix ills of the mind is 
certainly a powerful therapeutic ally.  In a return 
to the discussion of dose, interview results dem-
onstrated another way psychiatrists expound this 
clinical technique of harnessing patient belief and 
guiding meaning making.
4) Alterations, communication 
tactics and patient conceptualiza-
tions of dose levels.
Results.  Participants suggested that the majority 
of patients do not understand that different drug 
potencies relate to different doses.  For example, 
an average 20mg dose of fluoxetine seems much 
less potent than 125mg of buproprion — a below 
average dose of this antidepressant.  Transparency 
is necessary, participants contended, but they 
must take a nuanced approach.  For instance, 
one participant explained, if a patient thinks he 
is taking a very high dose, he may feel that his 
illness is more severe and be less likely to recover. 
Alternatively, if a patient understands his dose as 
very small, thereby having low expectations of its 
therapeutic ability, this knowledge can have a no-
cebo (negative placebo) effect.  Two participants 
therefore prefer leaving dose out of the conver-
sation as much as possible.  To avoid the nega-
tive influence that dose may have on patients, 
one participant often emphasizes: “The fact you 
need a high or low dose has nothing to do with 
being more or less ill, it is about what your body 
needs.  Some patients need high doses of medica-
tion, and that is okay, they may just have a fast 
metabolism.”
In situations where patients are anxious about 
taking medications, certain participants said they 
will carefully craft their wording and use phras-
es such as, “I am putting you on a microscopic 
dose,” “some people take ten times this dose and 
are just fine” or, “we are still not at the maximum 
dose level.”  On occasion, two participants will 
prescribe a lower dose solely because a patient 
is hesitant to begin drug treatment.  Conversely, 
participants also depicted patient anxiety about 
drug weaning.  In most instances, psychiatrists 
will proceed slowly.  One participant divulged 
that for patients who are more anxious and de-
pendent, it is not unusual to maintain them on 
a dose “that does not make sense for having a 
pharmacological effect but provides comfort for 
them.”  In such cases, the routine of coming to the 
clinic and receiving the low dose prescription can 
continue for years.
The majority of participants gave utmost pri-
ority to sharing as much information as possible 
with patients.  A few participants commented that 
elaborating on the scientific underpinnings of 
their decisions helps the patient understand what 
to expect from the medication and minimizes 
non-compliance.  For example, when starting a 
sub-therapeutic dose, participants will explain 
the tactic of building tolerance to the medication’s 
side effects.  Certain participants (N = 6) adopt 
a more cautionary approach and express to the 
patient that they do not expect any therapeutic 
benefits from the starting doses.  One participant 
reported that he will explain to patients that, “if 
they start to feel the side effects they may be for-
tunate enough to receive the therapeutic effects; 
at least the drug is doing something.”  These par-
ticipants explained that they are careful not to 
instill false hopes about the medications, largely 
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to prevent patient discouragement if the prescrip-
tion does not work.  Two participants went on to 
say that they rarely promote the placebo effect or 
use it in their practice.  
Discussion.  Communication is integral to the art 
of medicine and vital to good physicianship.  We 
typically consider dose, with its exacted milligram 
quantities of potent ingredients, as a key compo-
nent of the science of medicine.  Through the ex-
ploration of dose related questions, it is evident 
that dose modification represents an interface be-
tween the art and science of psychiatric practice. 
Participants highlighted opportunities to tailor 
the dose, or the communication of dose, in order 
to tilt the clinical situation in favour of positive 
patient expectancies.  On occasion, the protocol 
among participants to equip their patients with 
as much information as possible may work to the 
detriment of positive expectations.  Considering 
the evidence in support of placebo effects in the 
treatment of depression, it is difficult to ascertain 
how this full-disclosure approach aligns with the 
complexities of treating depression. 
By definition, a sub-therapeutic dose of 
medication constitutes a placebo-like treatment: 
it contains active ingredients but at insufficient 
doses to assume any therapeutic outcomes, indi-
vidual pharmacokinetic effects notwithstanding. 
Our findings suggest that the primary rationale 
for prescribing sub-therapeutic doses of antide-
pressants is for the patient to build tolerance and 
minimize adverse events.  The clinical stratagem 
of starting low and going slow, however, can pro-
duce surprising therapeutic outcomes at the ini-
tial, sub-therapeutic levels.  Psychiatrists seem to 
focus on the role of drug sensitivities in produc-
ing such outcomes and admit, albeit hesitantly, 
that factors other than pharmacology may be 
equally responsible for these effects. 
When presented with positive outcomes, 
psychiatrists have little incentive to uncover the 
source of sub-therapeutic drug efficacy.  For re-
searchers, on the other hand, the prescription of 
sub-therapeutic doses of antidepressants provides 
a unique paradigm for exploring the clinical role 
of placebo effects without the negative expectan-
cies and ethical issues of pure placebos.  The use 
of sub-therapeutic doses as an alternative to pla-
cebos, however, raises its own set of ethical issues 
surrounding monetary costs, potential harms, 
patient autonomy and professional form.  Under 
separate cover, we hope to soon provide a com-
prehensive account of the ethics of sub-therapeu-
tic dosing.
Our investigation of sub-therapeutic dosing 
practices sheds light on certain clinical realities 
of using non-drug factors in the pharmacologi-
cal treatment of depression.  Psychiatrists seem to 
entertain placebo effects in the nuances of psy-
chological manipulations involving dose com-
munication and expectancy-shaping techniques. 
In certain situations, moreover, dose alterations 
sustain psychological manipulations, as in the 
prescription of micro-doses to help allay the anx-
iety involved in starting or stopping a medication. 
When it comes to their intentions, however, psy-
chiatrists may shy away from deliberately seeking 
out placebo effects, even when they are using es-
sentially placebo-like treatments.  Nonetheless, 
placebo effects seem to have at least a candid role 
in the clinical treatment of depression.  
Limitations and Caveats
The present study constitutes a preliminary in-
vestigation of attitudes of practicing psychiatrists 
toward sub-therapeutic doses in relation to pla-
cebo effects in the context of depression.  Our 
main goal was to gauge how psychiatrists concep-
tualize and integrate these contentious topics in 
a clinical setting.  Although difficult to general-
ize, the nascent results provide valuable budding 
insights that will serve to guide further research 
investigations.
The limited number of interview subjects and 
the restricted analytical approach hinder our abil-
ity to generalize these findings to the wider medi-
cal community. Furthermore, the small study 
sample consisted only of academic psychiatrists 
(i.e. those working at hospitals and clinics affili-
ated with a university).  This tertiary care setting 
consists of specialists in psychiatric disorders, but 
this tier does not handle treatment for the ma-
jority of depressive cases.  In Canada, as in the 
United States and the United Kingdom, the bulk 
of cases fall to the primary care sector (Gilbody, 
et al., 2006; Goldman, Nielsen, & Champion, 
1999; MacMillan, Patterson, & Wathen, 2005; 
Michalak, 2002).  Results from the Mental 
Health and Well-Being portion of the Canadian 
Community Health Survey demonstrate that, of 
the Canadians suffering from the most preva-
lent mental conditions, 26% consulted a family 
physician at least once in the 12 months prior to 
the survey, whereas 12% and 8% consulted a psy-
chiatrist or psychologist respectively (Statistics 
Canada, 2003).  Of those seeking help for depres-
sion in the United States, nearly three quarters do 
so in the primary care setting (Goldman, et al., 
1999).  
Representation would not be a large issue if 
depression were treated similarly in the primary 
and tertiary care settings.  When interviewed, 
some psychiatrists said that their most satisfying 
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consultations arose from patients referred with 
“treatment resistant depression” by a primary 
care physician, only to see clinical benefits with a 
simple increase in dose.  According to those par-
ticipants who field primary care consults, poor 
pharmacological treatment outcomes often re-
sult from “sloppy” or inadequate dosing.  Several 
sources sustain these claims with reports of sub-
optimal depression treatment in the primary 
care setting (Eisenberg, 1992; Gilbody, Whitty, 
Grimshaw, & Thomas, 2003; Gilbody, et al., 2006; 
Katon, et al., 1992).
Our results demonstrate the complexities in-
volved in the treatment of depression; however, in 
order to closely understand the clinical realities, 
we must cast a wider net and address our ques-
tions to a broader audience with further research.
Conclusions
Exploring the nuances of sub-therapeutic dosing 
reveals subtleties in clinician behaviours that give 
merit to the role of placebo effects in the treat-
ment of depression.  Psychiatrists are often in the 
position of interpreting controversial research 
while exuding the clinical confidence of a care-
giver.  Converging on the clinically optimal dose 
requires mastery of the poorly understood dose-
response relationship for antidepressants while 
mediating the influence of individual differences. 
In addition, clinicians must consider the com-
monly accepted yet cautiously entrusted role of 
placebo effects in the recovery from depression. 
The chemical imbalance theory of depression, 
although scarcely validated, may play a role in 
shaping patient and clinician choices and expec-
tations of treatment.  The contributions — high-
lighted here and validated elsewhere — of patient 
choice (McPherson, 1994), knowledge (Entwistle, 
Sheldon, Sowden, & Watt, 1998), expectancy 
(Kirsch, 1999), and belief (Aikens, et al., 2005) 
to treatment outcomes may benefit from notions 
of specific neurochemical antidepressant action 
while collectively outperforming actual pharma-
cological action.  
The importance of portraying confidence in 
treatment to the patient (Thomas, 1987) and the 
perception that placebo effects are only transitory 
may be factors creating resistance to accepting 
recent lines of research that cast doubt on the 
clinical efficacy of antidepressants over placebos. 
An important consideration is that clinicians 
do not control for the non-drug effects of their 
prescriptions by comparing them to placebos. 
When clinicians observe therapeutic benefits 
upon an increase in antidepressant dose, we can-
not directly attribute this to a biochemical effect 
since research has demonstrated that placebos 
elicit a dose-response relationship in depression 
(Benkert et al., 1997) and in other conditions (De 
Craen et al., 1999). 
Our examination clarifies ambiguities sur-
rounding the use of sub-therapeutic doses of 
antidepressants for the treatment of depression. 
Several avenues of inquiry remain, particularly 
regarding the use of these low doses in primary 
care and in clinics unaffiliated with academia. 
We demonstrate that tacit knowledge and care-
fully crafted tactics are important in steering 
depressed patients towards recovery — perhaps 
more so than the ordinances of the existing 
evidence-based medicine.  Relinquishing these 
roles to general physicians, who currently see a 
disproportionately large number of depressed pa-
tients, creates a needless burden.  Psychological, 
neuroscientific and health directives on depres-
sion are abundant but far from comprehensive. 
Translating research results into meaningful clin-
ical practice should be a primary focus, as preva-
lence of depression continues to rise worldwide 
(Mathers & Loncar, 2006).  Policy and regula-
tory directives must concentrate on demanding 
evidence for lowest minimum effective doses of 
existing and emerging drug treatments.  “The 
dose makes the difference” (Moore, 1995) and in 
the antidepressant context, this may mean an ar-
bitrary difference between a drug and a placebo.
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e.g. A patient is transferred from another 
psychiatrist who already started them on 
a sub-therapeutic dose. e.g. The start low 
and go slow dose titration regimen. e.g. 
Using them as a diagnostic tool, trying to 
see if they are , patients complaints are not 
well-grounded, so one gives something 
very minimal to try and get the complaints 
to lift
a) Do these situations seem like rea-
sonable utilizations of sub-therapeutic 
doses? 
b) Do you often employ the start low 
and go slow doing regimen for antide-
pressant medication? 
- Do you often start the regime with a 
below average dose or an initial start-
ing dose that is known to be therapeu-
tically useful? 
6) Presume I came to you depressed, I 
showed the signs of moderate DSM-4 de-
pression, what would you prescribe for me 
and in what dose?  
7) Do you think adjunct drug therapy to 
psychotherapy means less of a dose is re-
quired than with drug therapy alone? 
8) What is your take on Kirsch and col-
leagues' meta-analyses on antidepressants 
versus placebos for depression?
9) Why do you think practice guidelines 
have barely changed in light of the evi-
dence that antidepressants aren't as effec-
Please describe the nature of your practice 
and your history treating depressed pa-
tients.
1) Do you find sub-therapeutic doses clini-
cally useful? 
- In what situations and for what types 
of patients, and types of disorders?
- What do people usually mean by sub-
therapeutic on the spectrum from a hair 
below therapeutic to just above homeo-
pathic? How does this compare to the 
term "low-dose"?
2) Out of curiosity, how would you define 
a sub-therapeutic dose if you had to come 
up with a definition?  
- Do you ever see surprising results at a 
very low dose?
3) If one were to say they have prescribed 
sub-therapeutic doses, would this equate 
to saying they have prescribed placebos?
4) How important do you think it is to 
communicate the dose level at least in 
qualitative terms to the patient to whom 
you are prescribing? For example, "I am 
prescribing you a high dose of the antide-
pressant fluoxetine." Why or why not?
- Do you see any ulterior psychological 
effects from the way you communicate 
dose levels?
5) There are 3 situations where sub-ther-
apeutic doses are admittedly employed: 
tive as we thought they were? What factors 
are creating resistance to accepting this 
kind of data? 
- How do you explain that there is no 
major up-roar, apart from a temporary 
wave of media publications (mostly in 
Europe) while many millions are taking 
antidepressants and affected by these 
results?
10) Do you think awareness of the results 
that cast doubt on the efficacy of antide-
pressants has in any way altered prescrip-
tion patterns on an individual physician or 
psychiatrist level? Or do guidelines nor-
mally change before any kind of change in 
practice takes place?
- What practice guideline do you usually 
follow for depression? Mix and match? 
Have you had the chance to read the lat-
est APA guidelines for depression?  
11) Do you see clinical trials as an effective 
means to study psychoactive drug efficacy?
- What is the relative weight of clinical 
experience in shaping prescription pat-
terns of antidepressants? 
12) Do you have any questions or com-
ments for me? Literature suggestions?
13) As a psychiatrist do you think this is a 
valid line of inquiry, is there something to 
unravel here? Is this something interesting 
for psychiatrists?
Appendix: Interview Question
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